
    
      OUTLINE: This is a multi-center study.

      Phase I: Patients will be accrued in the classic 3 patients per dose per cohort design,
      21-day cycle

        -  Dose Level 1 Everolimus 10 mg BNC105P 4.2 mg/m2

        -  Dose Level 2 Everolimus 10 mg BNC105P 8.4 mg/m2

        -  Dose Level 3 Everolimus 10 mg BNC105P 12.6 mg/m2

        -  Dose Level 4 Everolimus 10 mg BNC105P 16 mg/m2

      Phase II: Patients will be randomized 1:1 to Arm A or Arm B

      Combination Arm A: Everolimus 10 mg + BNC105P MTD (from Phase 1 study) 21 day cycle

      Sequential Arm B: Everolimus 10 mg 21 day cycle

        -  Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable
           toxicity on everolimus therapy.

      Karnofsky Performance Score (KPS) â‰¥70 within 7 days prior to registration for protocol
      therapy.

      Life Expectancy: Not specified

      Hematopoietic:

        -  White blood cell count (WBC) > 3.5 K/mm3

        -  Hemoglobin (Hgb) > 8.5 g/dL

        -  Platelets > 100 K/mm3

        -  Absolute neutrophil count (ANC) > 1.5 K/mm3

      Hepatic:

        -  Total Bilirubin < 1.25 x ULN

        -  Aminotransferase (AST and ALT) < 2.5 x ULN

      Renal:

        -  Serum Creatinine < 2.5 x ULN (upper limit normal)

      Cardiovascular:

        -  No significant cardiovascular events within 6 months (CVA, CAD, peripheral arterial
           obstruction, arrhythmias, cardiac dysfunction) of registration for protocol therapy

        -  No history of clinical CHF or LVEF <50% by Echo (or MUGA) within 30 days prior to
           registration for protocol therapy.
    
  